3 active not recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Istaroxime, Placebo - Cardiogenic Shock | Phase 1 / Phase 2 | Active not recruiting | Windtree Therapeutics | 20 | 2024-06-01 | 2025-08-20 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma iC9-CAR19 T cells, Bendamustine, Fludarabine - Lymphoma, Lymphoma, B-Cell | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2019-03-12 | 2026-07-31 |
| Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL iC9-CAR19 cells, Rimiducid, Cyclophosphamide - Acute Lymphoblastic Leukemia, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 15 | 2012-03-22 | 2026-06-10 |
Cytokine Release Syndrome (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Neurotoxicity Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Shock, Cardiogenic (1)
Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Hemic and Lymphatic Diseases (2) · Inflammation (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Systemic Inflammatory Response Syndrome (2) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Heart Diseases (1) · Hematologic Diseases (1) · Infarction (1) · Ischemia (1)
AP 1903 reagent (2) · Cyclophosphamide (2) · fludarabine (2) · fludarabine phosphate (2) · Bendamustine Hydrochloride (1) · Istaroxime (1) · Lactic Acid (1)
UNC Lineberger Comprehensive Cancer Center (2) · Windtree Therapeutics (1)
United States (3) · Argentina (1) · Israel (1) · Italy (1) · Poland (1)
Natalie Grover, MD (1) · Natalie S Grover, MD (1) · Steven G Simonson, MD (1)
K12CA120780 (1)